EClinCloud's eCOA Platform Reaches 177 Countries and Regions as Multi-Regional Trials Drive Electronic Outcome Capture

The electronic clinical outcome assessment solution now spans 40+ indication areas and 960+ collaborating sites across four continents, supporting all five COA types with end-to-end scale management, rater training and direct EDC integration.

NINGBO, China, Sept. 30, 2026 /PRNewswire/ -- EClinCloud, an AI technology company for clinical research that builds a unified clinical cloud platform and endpoint assessment technology to help improve trial success rates and shorten development cycles, today detailed the global reach of its eCOA solution: the company's electronic clinical outcome assessment application now operates in 177 countries and regions across four continents, with deployments spanning more than 40 indication areas and 960+ collaborating sites. The expansion tracks two reinforcing industry trends — international multi-regional clinical trials (MRCTs) taking an ever-larger share of new drug development, and outcome capture moving steadily from paper to electronic.

The company's own registry research puts numbers on the multi-regional shift. Its analysis of industry multinational drug-trial starts found China-inclusive MRCTs growing fivefold in a decade, from 65 starts in 2015 to 322 in 2025 — 28.6% of all such starts — with the median China-inclusive MRCT now spanning 15 countries and 90 facilities, against five countries and 27 facilities for multinational trials without China. On the assessment side, among phase 2/3 drug studies that name a widely used outcome instrument on ClinicalTrials.gov, one in three (33.1%) reports recruitment in multiple countries, and the top 1% span 22 countries or more.

The platform captures every major class of clinical outcome assessment on a single system: patient-reported outcomes (ePRO), clinician-reported outcomes (eClinRO), observer-reported outcomes (eObsRO), performance outcomes (ePerfO) and electronic diaries (eDiary). Because each assessment type implies a different workflow — who answers, on what device, on what schedule — running all five through one platform keeps a multi-country study's endpoint data on one backbone rather than scattered across point tools.

For MRCTs, deployment breadth is the operational test. EClinCloud delivers multilingual assessments in Chinese, English, Japanese and additional languages, including less widely spoken ones, and provides hardware and software as one service — PC, mobile app and tablet working in concert — so sites and patients in every region capture data the same way. The company's eCOA experience covers indication areas from CNS, oncology and dermatology to immunology, metabolic and endocrine disorders, respiratory disease and otolaryngology.

Privacy and compliance run through the deployment model. The platform is designed to meet the strict patient-privacy requirements of global data-protection regimes — GDPR in Europe, HIPAA in the United States and China's Personal Information Protection Law (PIPL) — while accommodating the marked differences between countries and regions in data-collection practice, cultural norms and regulatory enforcement, so that studies keep data consistent and compliant across every site.

"In a multi-regional trial, the hard part is no longer collecting a questionnaire — it is keeping every language, every rater and every device consistent and reliable across dozens of countries at once," said Michael Qin, PhD, Founder and Chief Executive Officer of EClinCloud. "That is why we built eCOA as an integrated solution with scale management, rater training and data connections around it, rather than as a standalone app."

Around the software, EClinCloud operates end-to-end scale management drawing on a rich scale library and multi-indication experience: scale due diligence, copyright licensing, translation and linguistic validation, and final delivery handled as one integrated workflow — the decision framework behind it is set out in the company's report "eCOA Linguistic Validation 2026: Translate, Adapt, License or Revalidate for a Multinational Trial?" The registry shows the scale of that work: the company's analysis found the VAS named in 19,413 registered studies, the EQ-5D in 8,317 and the SF-36 in 6,626, each carrying its own licensing, translation and validation requirements — a single instrument such as the EQ-5D-5L is maintained in more than 150 languages.

Complementing scale management, the company provides rater training to keep assessment results consistent and reliable across sites and raters — the discipline on which multi-regional endpoint quality depends. Its CNS analysis shows the scale of the need: 48.6% of 5,891 phase 2/3 CNS drug trials name a clinician-rated scale in an outcome, and 26.6% report sites in more than one country — and because public registries carry no field for rater qualification, consistency cannot be demonstrated from public records; it has to be built into the trial itself. The certification, inter-rater reliability and drift-monitoring framework behind the service is set out in the company's report "Clinical Trial Rater Training 2026: Certification, Inter-Rater Reliability and Drift Monitoring for CNS ClinRO Endpoints."

Assessment data does not sit in a silo. The eCOA platform integrates directly with EDC so endpoint data flows into a single casebook, while BI analytics assemble operational and clinical data into a full-picture view that supports faster, better-informed study decisions. AI-assisted capture adds a quality layer: in one pediatric Phase II study, AI-guided photo capture with real-time validation raised image pass rates from 40% to about 95% and cut rework cycles from 24–48 hours to under five seconds, with automatic privacy redaction at the point of capture.

In summary, the eCOA solution offers sponsors and study principal investigators running multi-regional trials:

• All five COA types — ePRO, eClinRO, eObsRO, ePerfO and eDiary — on one platform
• Multilingual deployment, with the eCOA app available in 177 countries and regions across four continents
• Experience across 40+ indication areas and 960+ collaborating sites
• Unified hardware-software delivery spanning PC, mobile app and tablet
• Integrated scale management: scale due diligence, copyright licensing, translation and linguistic validation, and delivery
• Rater training that safeguards the consistency and reliability of assessment results
• Direct EDC integration and BI analytics for decision support
• Privacy and compliance by design: built for GDPR, HIPAA and China's PIPL, bridging country-to-country differences in data-collection practice, culture and regulatory enforcement to keep data consistent and compliant

These capabilities are backed by EClinCloud's Deep Research series, which publishes the evidence base behind its platform and services. Recent reports also include "Multiregional Clinical Trials With China Sites in 2026: HGR Approval, PIPL Data Export and What the Registries Show," on the data-governance decisions MRCT sponsors face, with the full series available at https://www.eclincloud.com/insights.

For demonstrations and partnership inquiries, visit https://www.eclincloud.com/demo.

About EClinCloud

EClinCloud (Ningbo) Technology Co., Ltd. builds a unified, AI-driven clinical cloud platform and endpoint assessment technology for global pharmaceutical and research organizations, with a mission to become a global leader in AI-driven clinical research. Its integrated platform — EDC, RTSM, eCOA, IRC, CTMS, eTMF, resource management and eLearning, with embedded AI agents and BI analytics — supports 1,100+ clinical trials, 300+ organizations and 20,000+ users in 10+ countries and regions. EClinCloud is headquartered in Ningbo, China, with offices in Beijing, Shanghai, Chengdu, Shenzhen and New York. More information is available at https://www.eclincloud.com.

Company Contact

EClinCloud — Global Inquiries
EClinCloud (Ningbo) Technology Co., Ltd.
Phone: +86 186 1698 7169
Email: [email protected]
Web: https://www.eclincloud.com/demo

Media Relations

EClinCloud — Press Inquiries
Phone: +1 415 689 1868
Email: [email protected]

SOURCE EClinCloud